Table 2.
Clinical Trial of Immunotherapy for TNBC
| NCT | Subjects | Treatment | Status |
|---|---|---|---|
| 02768701 | Terminal TNBC | Cyclophosphamide, Pembrolizumab Injection | ANR |
| 04024800 | Terminal TNBC | AE37 peptide vaccination, Pembrolizumab Injection | R |
| 02977468 | Early TNBC (Node-negative) | Pembrolizumab Injection | R |
| 02555657 | Terminal TNBC | Pembrolizumab Injection | ANR |
| 02819518 | Terminal TNBC | Pembrolizumab Injection, Paclitaxel Injection (AlbuminBound) | ANR |
| 03639948 | Early TNBC | Pembrolizumab Injection | R |
| 03498716 | Early TNBC | Atezolizumab | R |
| 03164993 | Terminal TNBC | Atezolizumab | R |
| 03197935 | Early TNBC | Atezolizumab | ANR |
| 03012100 | Early TNBC | Cyclophosphamide, α-polypeptide vaccine | R |
Abbreviations: ANR, active, not recruiting; R, recruiting.